2012
DOI: 10.4049/jimmunol.1200396
|View full text |Cite
|
Sign up to set email alerts
|

A20 and CYLD Do Not Share Significant Overlapping Functions during B Cell Development and Activation

Abstract: The ubiquitin-editing enzyme A20 (TNFAIP3) and the deubiquitinase CYLD are central negative regulators of NF-kappa B signaling. Both can act by removing nonproteolytic K63-linked polyubiquitin chains from an overlapping set of signaling molecules. In B cells, A20 deficiency results in hyperactivity, loss of immune homeostasis, inflammation, and autoimmunity. The reported consequences of CYLD deficiency are controversial, ranging from an absence of effects to dramatic B cell hyperplasia. These differences could… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
15
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(16 citation statements)
references
References 51 publications
1
15
0
Order By: Relevance
“…This suggests that these ubiquitin editing enzymes are differentially regulated and have separate roles during normal aging. Along such lines, A20 and CYLD have been shown to have separate roles during B-cell activation with Toll-like receptor ligands (Chu et al, 2012). While in this study we implicate elevated A20 as a cause of ADMD, obtaining a more comprehensive understanding of how these deubiquitinases are regulated, their overlapping/distinct roles, and clarity in our understanding of their role during aging is important to understand how the innate immune system is altered during aging.…”
Section: Discussionmentioning
confidence: 99%
“…This suggests that these ubiquitin editing enzymes are differentially regulated and have separate roles during normal aging. Along such lines, A20 and CYLD have been shown to have separate roles during B-cell activation with Toll-like receptor ligands (Chu et al, 2012). While in this study we implicate elevated A20 as a cause of ADMD, obtaining a more comprehensive understanding of how these deubiquitinases are regulated, their overlapping/distinct roles, and clarity in our understanding of their role during aging is important to understand how the innate immune system is altered during aging.…”
Section: Discussionmentioning
confidence: 99%
“…Array data based on RNA transcript abundance at Genecards.org indicates that CYLD is found in low levels in a large percentage of somatic cells, with immune cells expressing more of it [24]. Unlike other deubiquitinases such as A20, CYLD is constitutively expressed, albeit at a low basal level [25, 26]. Regulation of both CYLD transcription and translation is highly variable, with multiple mechanisms available, including direct phosphorylation by kinases, treatment with allosteric caspase inhibitors like zVAD, protealytic cleavage, external serum receptor transduction and subsequent modification via kinases [such as SRF to MAPK and CaMKII pathways], control by other transcription factors and gene interactions, and direct binding by miRNAs [2737].…”
Section: Cyld Overviewmentioning
confidence: 99%
“…The other known substrates of MALT1 are all negative regulators of canonical NF-kB signaling. MALT1-dependent cleavage of the two ubiquitin editing enzymes, A20 and cylindromatosis (CYLD), downregulates their activity (12)(13)(14)(15). MALT1 also cleaves RelB, priming it for proteasomedependent degradation (16) and resulting in modulation of canonical NF-kB activation via the release of RelA and c-Rel.…”
mentioning
confidence: 99%